Join us to hear from Frank David, MD, PhD, co-author of “The Pharmagellan Guide to Biotech Forecasting and Valuation”, about valuing biotech assets (small molecule drugs, biologics), a crucial exercise when evaluating publicly traded biotech companies, licensing deals, potential M&A, early-stage venture investments, and even your own biotech startup!
“All models are wrong, but some are useful” – How to approach financial models in biotech
Patients, patients, patients – The importance of bottom-up market sizing
Resisting the siren call of customization – How and when to adjust literature values for key inputs
- “We’re only worth WHAT?” – Managing expectations of the “consumers” of biotech models